Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Eribulin Mesylate
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Breast Cancer
Fabricant:
Eisai Ltd.
Brand Name:
Halaven
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0005-000
Strength:
1mg per 2 mL vial
Tumour Type:
Breast
Indications:
Metastatic Breast Cancer
Review Status:
Complete
Date NOC Issued:
Sponsor:
Eisai Ltd.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
Funding Request *Revised at Submitter's request:
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane administered in either the adjuvant or metastatic setting.
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016